Eric F. Morand Grant/research support from: AstraZeneca, Consultant of: AstraZeneca, Speakers bureau: AstraZeneca
DOI: 10.1136/annrheumdis-2020-eular.3007

AB0385

TARGETING CD38 IN SYSTEMIC LUPUS ERYTHEMATOSUS

L. Ostendorf^{1,2}, U. Schneider¹, M. Urbicht², P. Enghard^{2,3}, F. Heinrich², P. Durek², G. Heinz², H. Mei², M. F. Mashreghi², G. R. Burmester¹, A. Radbruch², F. Hiepe^{1,2}, T. Alexander^{1,2}. ¹Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; ²Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany; ³Charité – Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany

Background: Depletion of long-lived plasma cells (PC) resembles a novel concept for the treatment of antibody-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE). Therapeutic approaches such as autologous stem-stem cell transplantation and proteasome inhibition are limited by significant treatment-related toxicity. A novel target for PC depletion is CD38, a surface protein that is highly expressed on plasma cells (PCs) but also activated T-cells and most myeloid cells. Daratumumab is a monoclonal antibody targeting CD38 that is licensed for the treatment of multiple myeloma.

Objectives: Here, we aimed to ascertain clinical safety and efficacy of Daratumumab for the treatment of refractory SLE, as well as to gain insights into effects of Daratumumab on the immune system.

Methods: We treated two SLE patients with life- and organ-threatening SLE with four weekly doses of 16 mg/kg Daratumumab. We performed integrative analyses of clinical, serological and immunological effects over a follow-up period of 6 months. Using flow cytometry and single-cell RNA and T-cell receptor sequencing we followed CD38 expression and composition of peripheral blood leukocytes with a special focus on memory T cells.

Results: Patient 1, a 50-year old woman, suffered from active biopsy-proven class III lupus nephritis (LN) with nephrotic syndrome, pericarditis, arthritis and skin rash. Upon Daratumumab treatment, her glomerular filtration rate normalized within 3 months and proteinuria gradually declined from 6.4 to 1.9g/g Creatinine during the 180-day follow-up period. Pericarditis, arthritis and skin rash completely resolved. Patient 2, a 32-year-old woman, presented with autoimmune hemolytic anemia requiring blood transfusions, immune thrombocytopenia and cutaneous vasculitis. Her direct antiglobulin test normalized within 3 months and remained negative throughout follow-up with consecutive recovery of the hemolytic anemia. Immune thrombocytopenia stabilized and vasculitic skin lesions completely resolved. Infusions were well tolerated without severe adverse drug reactions. NK cells and Dendritic Cells were transiently depleted, while numbers of T cells, B cells and Monocytes in the peripheral blood remained stable. CD38+ memory T cells that were expanded prior to treatment were virtually undetectable early after treatment. Their single cell transcriptomics demonstrated an upregulation of genes associated with activation, cytotoxicity and type 1 interferon response. CD38+ CD8+ memory T-cells showed marked oligoclonality. These prominent clones persisted upon treatment but their transcription profile gradually normalized.

Conclusion: Daratumumab appears to be a safe and effective treatment for refractory SLE. Further investigations are warranted to establish the efficacy in a clinical trial and to gain further insights into the pathophysiologic mechanism of action.

Disclosure of Interests: Lennard Ostendorf: None declared, Udo Schneider: None declared, Marie Urbicht: None declared, Philipp Enghard: None declared, Frederik Heinrich: None declared, Pawel Durek: None declared, Gitta Heinz: None declared, Henrik Mei: None declared, Mir-Farzin Mashreghi: None declared, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Andreas Radbruch: None declared, Falk Hiepe: None declared, Tobias Alexander: None declared

DOI: 10.1136/annrheumdis-2020-eular.5052

AB0386

RITUXIMAB IN LUPUS NEPHRITIS. REAL CLINICAL PRACTICE

C. Ramos Giráldez¹, M. L. Velloso Feijoo², S. Rodríguez Montero², J. L. Marengo². ¹Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain; ²Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain

Background: Lupus nephritis (LN) is a potentially life-threatening complication of systemic lupus erythematosus (SLE). Standard treatment of this entity includes glucocorticoids (GC) and immunosuppressants such as cyclophosphamide (CF), with remission rates between 20 and 70%. Given its pathogenesis, the anti-CD20 antibody rituximab (RTX) may be useful, although the information available in the scientific literature remains controversial.

Objectives: To evaluate the effectiveness and safety of RTX in NL refractory to conventional treatment, under real clinical practice conditions.

Methods: Retrospective descriptive observational study, which included consecutive patients attended in a Rheumatology Unit who met SLICC 2012 criteria for SLE, with renal involvement, and who had received RTX for NL refractory to standard treatment. We collected different epidemiological, clinical (including other manifestations of SLE as well as previous treatments), analytical, RTX-related and adverse event variables. In all cases, renal function prior to the initiation of RTX was determined, as well as the degree of proteinuria and sediment alterations. The therapeutic response was evaluated considering partial response if they presented reduction of proteinuria in >50% compared to initial and stabilization of renal function ($\pm 25\%$) or improvement of serum creatinine with respect to initial values; and complete response if they presented levels of serum creatinine <1.2mg/dL (or decrease to initial values or $\pm 15\%$ of the basal value in those with creatinine ≥ 1.2 mg/dL), proteinuria ≤ 0.5 g/24h and inactive sediment. A quantitative descriptive analysis has been carried out with the statistical program IBM SPSS 24.0 for Windows.

Results: Thirteen patients (11 women and 2 men) were included, with a mean age of 32.3 years and a mean follow-up time from the start of RTX of 11.09 years. Class IV NL was the most frequent (46.15%), followed by Class III NL (38.46%). Class V NL represented 7.69% and another 7.69% the combination of Class III+V. Renal failure was present in 46.2% of patients at the beginning of RTX, 84.6% hematuria and all patients presented proteinuria, of which 76.9% were confirmed to have nephrotic range and 84.6% showed hypoalbuminemia. With regard to previous treatments, all cases had received high-dose of GC and at least one immunosuppressant: 92.3% had failed to CF, a similar percentage had received azathioprine and 46.2% had failed to mycophenolate. After treatment with RTX, partial or complete response was achieved in 84.61%, infections were identified in 46.15% of patients and allergic reactions in 15.38%; most adverse events were mild and all cases developed favorably.

Conclusion: RTX treatment is effective in SLE and specifically in LN. More than 80% of patients in our study with refractory LN benefited from RTX treatment. Despite the not insignificant incidence of adverse events, most were mild and resolved without sequels or complications, so we can conclude that the safety of RTX is acceptable and should be considered as a treatment option for these patients according to the good risk-benefit profile.

Disclosure of Interests: Consuelo Ramos Giráldez: None declared, Maria Luisa Velloso Feijoo: None declared, Sergio Rodríguez Montero: None declared, Jose Luis Marengo Speakers bureau: AbbVie, Pfizer, Lilly

DOI: 10.1136/annrheumdis-2020-eular.4305

AB0387

TREATMENT STATUS FOR OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CROSS-SECTIONAL ANALYSIS FROM A LUPUS REGISTRY OF NATIONWIDE INSTITUTIONS (LUNA)

K. E. Sada¹, K. Hayashi¹, Y. Asano¹, Y. Katayama¹, S. Hiramatsu Asano¹, K. Ohashi¹, M. Morishita¹, H. Watanabe¹, M. Narazaki¹, Y. Matsumoto¹, N. Yajima², R. Yoshimi³, Y. Shimojima⁴, S. Ono⁵, H. Kajiyama⁶, K. Ichinose⁷, S. Sato⁸, M. Fujiwara⁹, J. Wada¹. ¹Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; ²Showa University School of Medicine, Tokyo, Japan; ³Yokohama City University Graduate School of Medicine, Yokohama, Japan; ⁴Shinshu University School of Medicine, Matsumoto, Japan; ⁵Yokohama City University Medical Center, Yokohama, Japan; ⁶Saitama Medical University, Saitama, Japan; ⁷Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; ⁸Fukushima Medical University School of Medicine, Fukushima, Japan; ⁹Yokohama Rosai Hospital, Yokohama, Japan

Background: Osteoporosis is one of the most important adverse effects of glucocorticoids in patients with systemic lupus erythematosus (SLE). Because osteoporosis is accelerated by chronic kidney disease (CKD), more attention should be paid to the treatment for osteoporosis in SLE patients with CKD. Many treatment options for osteoporosis have emerged recently, but treatment status in patients with SLE is not elucidated.

Objectives: The purpose of this study is to elucidate the treatment status for osteoporosis in patients with SLE among the CKD stages.

Methods: Using data from lupus registry of nationwide institutions (LUNA), a cross-sectional analysis was performed. We firstly described treatment status for osteoporosis in all enrolled patients. Secondary, treatment status for osteoporosis was compared among CKD stages. Finally, bone damage in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was compared among CKD stages.

Results: The median age (interquartile range [IQR]) of enrolled 917 patients was 44 (34–57) years and 809 patients (88%) were female. CKD stages were follows: CKD stage 1, 234 (26%); CKD stage 2, 465 (51%); CKD stage 3, 189 (21%); CKD stage 4, 9 (1%); CKD stage 5, 16 (2%). Median (IQR) age, female sex,